Complexities in Childhood Skin Conditions: Being at the Forefront of Care
The ever-increasing presence of a variety of dermatologic conditions across the lifespan, including in neonates, children, and adolescents continues to be a major challenge for healthcare providers in the United States. Current estimates predict that up to 30% of primary care visits in the US involve a skin-related issue, with some of the most common conditions including atopic dermatitis, seborrheic dermatitis, contact dermatitis, acne, neonatal rashes, and sunburn among others (Castelo-Soccio 2017). There is a shortage of pediatric dermatologists in the United States, and more often the burden of care falls to the dermatologists, pediatricians, and family care physicians (Castelo-Soccio 2017). Given the burgeoning field of clinical dermatology, this course will provide a unique opportunity to pediatricians to get additional education on the diagnosis and treatment of common dermatologic conditions they see in everyday practice.
This activity is designed to meet the needs of pediatric dermatologists, pediatricians, family practitioners, dermatologists, nurses/nurse practitioners and residents in these programs.
Upon completion of the educational activity, participants should be able to:
- Identify effective patient/caretaker communication and education strategies to improve patient adherence to prescribed therapy for chronic dermatologic conditions.
- Interpret the efficacy and safety of available treatment options for moderate-to-severe and/or recalcitrant acne.
- Develop individualized treatment regimens for pediatric patients with difficult to treat acne that promote antibiotic stewardship and optimize long-term.
- Identify recent advances in pediatric atopic dermatitis knowledge and treatment.
- Examine the efficacy and safety of current non-pharmacological and pharmacological treatments for AD patients across the age spectrum.
- Identify therapeutic advances for infantile hemangiomas and vitiligo in the pediatric population.
- Discuss recent therapeutic updates for hyperhidrosis, acne, warts, and molluscum in the pediatric population.
- Identify current and upcoming biologics used in the treatment and management of pediatric psoriasis.
Lawrence A. Schachner, M.D.
Professor, Chair Emeritus & Stiefel Laboratories Chair
Director of the Division of Pediatric Dermatology
Dr. Phillip Frost Department of Dermatology & Cutaneous Surgery
Professor of Pediatrics
University of Miami Miller School of Medicine
Mercedes E. González, MD, FAAD
Medical Director, Pediatric Dermatology of Miami
Assistant Professor, University of Miami Miller School of Medicine,
Dr. Phillip Frost Department of Dermatology and Herbert Wertheim College of Medicine
Latanya Benjamin, MD, FAAD, FAAP
Associate Professor of Pediatric Dermatology
CME/CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDERM. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 3.5 Contact Hours.
Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDERM
Latanya T. Benjamin, MD, FAAD, FAAP
Medical Advisory Board
Chapter Author for Up to Date
Regeneron and Sanofi Genzyme
Mercedes Gonzalez, MD
Dermavant, Regeneron Pharmaceuticals, Unilever, Inc, Verrica Pharmaceuticals
AbbVie, Inc, Novan, Pfizer, Regeneron Pharmaceuticals, Verrica
Galderma, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme
Lawrence A. Schachner, MD
Celgene, Pfizer, Sanofi/Genzyme, Regeneron
Dorothy Caputo, MA, BSN, RN - CE Director of Accreditations
Nothing to disclose
Bernadette Marie Makar, MSN, NP-C, APRN-C- BC- Nurse Planner
Nothing to disclose
AKH and LiVDERM Planners and Reviewers
Nothing to disclose
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
- 3.50 AMA PRA Category 1 Credit™
- 3.50 ANCC
- 3.50 Participation
A computer with an internet connection.
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.